SAB BIOTHERAPEUTICS, INC. (SABS) Free cash flow
- Free cash flow · 12 months (USD): Value (m); Formula and calculation Operating cash flow minus capital spending; distinct from the saved levered FCF quote figure. Period ending 2026-06-30..
- Price / free cash flow · 12 months: Value (m); Formula and calculation Market cap / trailing-year free cash flow; inverse of FCF yield before percent scaling. Period ending 2026-06-30..
- Free cash flow yield · 12 months: Value (m); Formula and calculation (Operating cash flow − capital spending) / current market cap. Period ending 2026-06-30..
- Free cash flow margin · 12 months: Value (m); Formula and calculation (Operating cash flow − capital spending) / revenue. Period ending 2026-06-30..
Free cash flow
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Free cash flow · 12 months (USD) | (m) | Operating cash flow minus capital spending; distinct from the saved levered FCF quote figure. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Price / free cash flow · 12 months | (m) | Market cap / trailing-year free cash flow; inverse of FCF yield before percent scaling. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Free cash flow yield · 12 months | (m) | (Operating cash flow − capital spending) / current market cap. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Free cash flow margin · 12 months | (m) | (Operating cash flow − capital spending) / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Free cash flow per share · 12 months | (m) | (Trailing-year operating cash flow − capital spending) / reported quarter-end common shares. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Operating cash flow · 12 months | $-53.94M | Cash generated by operating activities. Period ending 2026-06-30. |
| Operating cash flow / net income · 12 months | 4.22× | Operating cash flow / net income. Period ending 2026-06-30. $-53.94M ÷ $-12.78M ≈ 4.22× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating cash flow | -53.94M USD | Net Cash Provided by (Used in) Operating Activities |
| Capital spending | (m) | Payments to Acquire Property, Plant, and Equipment |
| Market cap | (m) | |
| Free cash flow | (m) | Net Cash Provided by (Used in) Operating Activities · Payments to Acquire Property, Plant, and Equipment |
| Revenue | (m) | Revenue from Contract with Customer, Excluding Assessed Tax |
| Quarter-end shares | (m) | Common Stock, Shares, Outstanding |
| Net income | -12.78M USD | Net Income (Loss) Attributable to Parent |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Free cash flow | FCF per share | Operating cash flow | Capital spending (USD) | Market cap (USD) | Revenue (USD) | Quarter-end shares (shares) | Net income (USD) | Price / FCF | FCF yield | FCF margin | Cash conversion |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | (m) | $-53.94M | (m) | (m) | (m) | (m) | $-12.78M | (m) | (m) | (m) | 4.22× |
| 2026-03-31 | (m) | (m) | $-51.25M | (m) | (m) | (m) | (m) | $-398.43K | (m) | (m) | (m) | 128.63× |
| 2025-12-31 | $-45.71M | (m) | $-44.78M | $933.16K | (m) | $0.00 | (m) | $13.27M | (m) | (m) | (m) | -3.37× |
| 2025-09-30 | (m) | (m) | $-37.53M | (m) | (m) | (m) | (m) | $18.74M | (m) | (m) | (m) | -2.00× |
| 2025-06-30 | (m) | (m) | $-30.77M | (m) | (m) | (m) | (m) | $-37.06M | (m) | (m) | (m) | 0.83× |
| 2025-03-31 | (m) | (m) | $-31.34M | (m) | (m) | (m) | (m) | $-34.28M | (m) | (m) | (m) | 0.91× |
| 2024-12-31 | $-34.63M | (m) | $-34.29M | $337.26K | (m) | $1.32M | (m) | $-34.11M | (m) | (m) | -2618.65% | 1.01× |
| 2024-09-30 | $-38.56M | (m) | $-38.21M | $349.75K | (m) | $1.51M | (m) | $-45.57M | (m) | (m) | -2548.80% | 0.84× |
| 2024-06-30 | $-37.42M | (m) | $-37.08M | $334.75K | (m) | $2.78M | (m) | $-40.32M | (m) | (m) | -1345.90% | 0.92× |
| 2024-03-31 | $-34.57M | (m) | $-34.26M | $304.93K | (m) | $2.60M | (m) | $-39.87M | (m) | (m) | -1328.30% | 0.86× |
| 2023-12-31 | $-25.32M | (m) | $-25.12M | $197.15K | (m) | $2.24M | (m) | $-42.19M | (m) | (m) | -1130.71% | 0.60× |
| 2023-09-30 | $-13.47M | (m) | $-13.23M | $247.04K | (m) | $4.09M | (m) | $-27.21M | (m) | (m) | -329.07% | 0.49× |
| 2023-06-30 | $-16.22M | (m) | $-15.98M | $240.24K | (m) | $6.42M | (m) | $-29.19M | (m) | (m) | -252.74% | 0.55× |
| 2023-03-31 | $-16.36M | (m) | $-15.53M | $830.39K | (m) | $12.68M | (m) | $-27.08M | (m) | (m) | -128.98% | 0.57× |
| 2022-12-31 | $-25.63M | (m) | $-23.46M | $2.17M | (m) | $23.90M | (m) | $-18.74M | (m) | (m) | -107.20% | 1.25× |
| 2022-09-30 | $-31.19M | (m) | $-26.78M | $4.41M | (m) | $32.80M | (m) | $-22.42M | (m) | (m) | -95.10% | 1.19× |
| 2022-06-30 | $-22.37M | (m) | $-14.81M | $7.56M | (m) | $43.89M | (m) | $-19.40M | (m) | (m) | -50.97% | 0.76× |
| 2022-03-31 | $-26.40M | (m) | $-15.99M | $10.41M | (m) | $55.75M | (m) | $-17.57M | (m) | (m) | -47.35% | 0.91× |
| 2021-12-31 | $-7.19M | (m) | $3.76M | $10.94M | (m) | $60.88M | (m) | $-17.14M | (m) | (m) | -11.80% | -0.22× |
| 2021-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |